ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2026
Effect of COVID-19 Pandemic on Epidemiology and Antimicrobial Susceptibility of Campylobacter Species, Salmonella enterica and Yersinia enterocolitica in Southwest Finland 2018-2022.
Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the effect of the COVID-19 pandemic on the epidemiology and antimicrobial susceptibility of fecal Campylobacter spp., Salmonella enterica, and Yersinia enterocolitica strains in Southwest Finland from 2018 to 2022. Results show that the number of travel-associated S. enterica and Campylobacter spp. declined markedly from autumn 2019 to autumn 2020 and have recovered gradually. Antimicrobial susceptibility testing was performed on bacterial strains isolated from PCR-positive fecal specimens. Resistance patterns fluctuated throughout the study period. Among C. jejuni, ciprofloxacin resistance averaged 58% in domestic (n = 155) and 88% travel-associated (n = 10) strains, while tetracycline resistance averaged 36% and 63%, respectively; erythromycin resistance was not detected. In S. enterica, resistance averaged 42% and 33% to ampicillin, 33% and 45% to fluoroquinolones, 4% and 6% to cefotaxime, and 0% and 2% to co-trimoxazole, in domestic (n = 24) and travel-associated (n = 32) strains, respectively. Among domestic Y. enterocolitica strains (n = 64), resistance averaged 7% to co-trimoxazole, 2% to ciprofloxacin, and 1% to cefotaxime; no travel-associated strains were reported. This study shows that lockdowns due to the COVID-19 pandemic decreased the number of diagnosed enteropathogens and limited the emergence of resistant strains. Thus, our results reaffirm that travel remains the primary source of S. enterica infections in Finland.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.